Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceralasertib - AstraZeneca/University of Pennsylvania

X
Drug Profile

Ceralasertib - AstraZeneca/University of Pennsylvania

Alternative Names: AZD 6738

Latest Information Update: 15 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; University of Pennsylvania
  • Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
  • Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Cholangiocarcinoma; Gastric cancer; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Preclinical Diffuse large B cell lymphoma; Type 1 diabetes mellitus
  • No development reported B-cell lymphoma; Chronic myelomonocytic leukaemia; Head and neck cancer; Lymphoid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Discontinued Haematological malignancies

Most Recent Events

  • 05 Apr 2024 Efficacy, pharmacokinetics and adverse events data from the phase IIa PLANETTE trial in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 08 Jan 2024 NHS Greater Glasgow, Clyde Health Board and AstraZeneca terminates a Phase-II clinical trials in Pancreatic cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, In adolescents, In adults, In the elderly) in United Kingdom (PO)due to lack of staff/facilities/resources as of January 2024 (EudraCT2018-003971-37) (ISRCTN16004234)
  • 25 Oct 2023 Samsung Medical Center in collaboration with AstraZeneca completes a phase II SUKSES-N4 trial for Small cell lung cancer (Combination therapy, Second line therapy or greater) in South Korea (IV) (NCT04361825)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top